Portal de Periódicos da CAPES

Pulmonary Complications of Pediatric Hematopoietic Cell Transplantation. A National Institutes of Health Workshop Summary

2020; American Thoracic Society; Volume: 18; Issue: 3 Linguagem: Inglês

10.1513/annalsats.202001-006ot

2329-6933

Robert F. Tamburro, Kenneth R. Cooke, Stella M. Davies, Samuel Goldfarb, James S. Hagood, Ashok Srinivasan, Marie E. Steiner, Dennis C. Stokes, Nancy DiFronzo, Nahed El-Kassar, Nonniekaye Shelburne, Aruna Natarajan, Neil R. Aggarwal, Michael Boeckh, Guang-Shing Cheng, Alpana Waghmare, Joshua A. Hill, Larissa Broglie, Jason W. Chien, Shane Cross, Jennifer McArthur, Christine Duncan, Leslie E. Lehmann, Christina Ullrich, Brian T. Fisher, Gerhard Hildebrandt, Robert R. Jenq, Kris M. Mahadeo, Sonata Jodele, James P. Kiley, Valerie Maholmes, Bethany B. Moore, Gregory A. Yanik, Lawrence M. Nogee, Sophie Paczesny, Courtney M. Rowan, Kirk R. Schultz, Kirsten M. Williams, Jason C. Woods, Matt S. Zinter,

Hematopoietic Stem Cell Transplantation

Approximately 2,500 pediatric hematopoietic cell transplants (HCTs), most of which are allogeneic, are performed annually in the United States for life-threatening malignant and nonmalignant conditions. Although HCT is undertaken with curative intent, post-HCT complications limit successful outcomes, with pulmonary dysfunction representing the leading cause of nonrelapse mortality. To better understand, predict, prevent, and/or treat pulmonary complications after HCT, a multidisciplinary group of 33 experts met in a 2-day National Institutes of Health Workshop to identify knowledge gaps and research strategies most likely to improve outcomes. This summary of Workshop deliberations outlines the consensus focus areas for future research.